What's in Cardiol Therapeutics Inc.'s pipeline?

Cardiol Therapeutics Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Cardiol Therapeutics Inc.'s portfolio?

Top competitors by shared drug class: Direct Biologics, LLC, Instituto de Oftalmología Fundación Conde de Valenciana.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cardiol-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Cardiol Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Cardiol Therapeutics Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
CardiolRx	CardiolRx	phase 3	Exosome therapy		Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Direct Biologics, LLC · 1 shared drug class
Instituto de Oftalmología Fundación Conde de Valenciana · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cardiol Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Cardiol Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cardiol-therapeutics-inc. Accessed 2026-05-16.